Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lestaurtinib with standard chemotherapy for relapsed FLT3-mutated acute myeloid leukemia
2005-002258-23Phase 2Completed
- Sponsor
- Cephalon, Inc.
- Start
- Sep 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lestaurtinib in acute myeloid leukemia (AML) (2 arms), sponsored by Cephalon, Inc. Primary endpoint: Complete remission at outcome assessment. Started Sep 2005; status: completed.
02
Drugs
lestaurtinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2005-002258-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002258-23.